

PROBLEM

This patient's CYP2C19 genotype is associated with very impaired metabolic activation of the prodrug clopidogrel (Plavix) and elevated risk for stent thrombosis or other cardiovascular events following PCI.

REASONS

Reduced clopidogrel activation in this genotype results in significantly reduced platelet inhibition, increased residual platelet aggregation, and decreased clopidogrel efficacy.

RECOMMENDATIONS - MODIFY TREATMENT BY CHOOSING ONE OF THE FOLLOWING:

(A) Prescribe prasugrel (EFFIENT) 10 mg daily

*Contraindications: History of stroke or transient ischemic attack, active bleeding

*Caution: Increased bleeding risk: Age > 75 years, Body weight < 60 kg

OR

(B) Prescribe ticagrelor (BRILINTA) 90mg twice daily

*Contraindications: History of intracranial hemorrhage, active bleeding, severe hepatic impairment

*Caution: Aspirin doses > 100 mg/day reduce ticagrelor effectiveness and should be avoided.

[More information on clopidogrel and CYP2C19](#)

Last CYP2C19=*2/*8 on 4/12/2012

Acknowledge Reason:



- Open order: Place order for prasugrel (EFFIENT) 10 mg daily. Note: remove order for clopidogrel on next screen.
(Last done by Ellen Kershner at 2:50 PM on 4/16/2012)
 - Open order: Place order for ticagrelor (BRILINTA) 90 mg twice daily. Note: remove the clopidogrel order on next screen.
(Last done by Inpatient Physician, MD at 12:12 PM on 5/16/2012)
 - Open order: Proceed with clopidogrel (PLAVIX) 75 mg daily. Note: please remove the bottom or second clopidogrel order as it will duplicate.
(Last done by Inpatient Physician, MD at 12:17 PM on 4/26/2012)
- Message sent: This alert has been sent via In Basket

Accept

Cancel